biOasis Technologies Inc. (TSX.V:BTI) (OTCMKTS:BIOAF) use of peptides to transport therapeutic drugs across the blood brain barrier is attracting the attention of major biotech partners.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
Krishan Maggon 's curator insight,
December 9, 2014 12:53 PM
ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in MiceAnthony Regina, Michel Demeule, Sasmita Tripathy, Simon Lord-Dufour,Jean-Christophe Currie, Mustapha Iddir, Borhane Annabi, Jean-Paul Castaigne,and Jean E. LachowiczMol Cancer Ther; Published OnlineFirst December 9, 2014; doi:10.1158/1535-7163.MCT-14-0399Molecular Cancer Therapeutics OnlineFirst
Last updated December 9, 2014 The LRP-1 Solution: Robust and VersatileThe blood-brain barrier (BBB) does a very good job of preventing most natural molecules and foreign substances from entering the brain via the BBB’s tight junctions of endothelial cells and P-glycoprotein (P-gp) activity. Essential substances like insulin and growth hormones are able to successfully enter the brain using receptors in the BBB. One of the most important receptors involved in that transport process is lipoprotein receptor-related protein, or LRP-1. By engineering drugs that bind to the LRP-1 receptor, Angiochem has created therapeutics that are able to permeate the BBB while maintaining their activity and efficacy. Binding Drug Compounds to the Body’s Own LRP-1 ReceptorAngiochem's proprietary, proven, and highly versatile technology platform uses the body’s own receptors, specifically Angiochem’s drugs bind to the LRP-1 receptor, and cross the BBB through LRP-1 receptor mediated transcytosis, which is the same natural process by which substances like insulin enter the brain. |
Krishan Maggon 's curator insight,
December 15, 2014 4:03 AM
Front. Cell. Neurosci., 12 December 2014 | doi: 10.3389/fncel.2014.00418Gliomas and the vascular fragility of the blood brain barrierLuiz Gustavo Dubois1†, Loraine Campanati2†, Cassia Righy1, Isabella D’Andrea-Meira1, Tania Cristina Leite de Sampaio e Spohr1, Isabel Porto-Carreiro1, Claudia Maria Pereira3, Joana Balça-Silva4, Suzana Assad Kahn1, Marcos F. DosSantos2, Marcela de Almeida Rabello Oliveira5, Adriana Ximenes-da-Silva5, Maria Celeste Lopes4, Eduardo Faveret1, Emerson Leandro Gasparetto1 and Vivaldo Moura-Neto1,2*
Krishan Maggon 's curator insight,
November 21, 2014 4:47 AM
biOasis’ Transcend Platform is a group of proprietary technologies designed for the transport of therapeutic agents across the blood brain barrier (“BBB”) and into the brain tissue. The delivery of therapeutics across the BBB represents the single greatest challenge in the treatment of over a thousand common and rare diseases of the brain and central nervous system. The development of an effective method to deliver therapeutics across the BBB has been considered for decades to be the “Holy Grail” of neurological medicine. Transcend ProgramMTfTranscend is based on the naturally occurring transport protein, melanotransferrin, also called MTf, CD228 and p97. Found at low concentrations in the blood, MTf is able to cross the BBB through a process called Receptor Mediated Transcytosis (“RMT”) where MTf molecules attach to receptors on the cells of the BBB. MTf is then pulled through the cells and into the brain where the MTf molecules can deliver their payload. With biOasis’ proprietary Transcend carrier, the MTf protein can be attached to therapeutics of varying sizes or types. When infused or injected as a therapeutic, the resulting structure attaches itself to a BBB receptor and is pulled across the BBB where the therapeutic payload is delivered to brain. biOasis has shown that Transcend can deliver a wide variety of therapeutics to brain, including antibodies, enzymes, siRNA and small molecule drugs, which together are expected to treat neurological diseases in several areas, including brain cancers, neurodegenerative and metabolic diseases. MTfpThrough extensive research, the biOasis team identified the peptide portion within MTf that was responsible for crossing the BBB. The peptide, named MTfp, was shown to transport therapeutic agents across the BBB more readily than the original Transcend. biOasis filed patent protection for the peptide and its related forms, which would result in extending the Company’s intellectual property for another 20 years. The peptide was branded “MTfp” and is now the Company’s main focus. Benefits of The Peptide DiscoveryMTfp is less than 2% the size of the original MTf protein, which is advantageous because: MTfp has a higher commercial value than MTf.MTfp can be produced at a fraction of the cost of MTf.Quality Assurance is far easier with MTfp than with MTf.MTfp allows for rapid and reproducible synthesis of Transcend-based therapeutics.MTfp has a longer shelf life than MTf, resulting in longer storage times.MTfp can be linked to therapeutics with greater control and efficiency than MTf.biOasis is actively engaged in the development and commercialization of its proprietary Transcend Platform and a newly discovered peptide derived from MTf for the transport of therapeutic agents across the BBB to the central nervous system (CNS). |